AI tools are faster at drafting clinical trial documents, but human writers remain indispensable for logical reasoning.

Shares of IQVIA Holdings Inc. IQV slipped 8.79% to $143.22 Thursday, on what proved to be an all-around poor trading session ...

Products made here might still depend on materials from overseas. And they might be made on machines needing foreign replacement parts.

Current observations and foresight into the world of biosimilars, GLP-1s, PBM and payer trends, according to Jeff Casberg, MS ...

IQVIA Holdings (IQV) shares soared 8.7% in the last trading session to close at $157.02. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares ...

Biocon Biologics has received the Food and Drug Administration’s green light for Jobevne (bevacizumab-nwgd), a biosimilar ...

Fintel reports that on April 10, 2025, Barclays downgraded their outlook for IQVIA Holdings (NYSE:IQV) from Overweight to Equal-Weight. Analyst Price Forecast Suggests 58.50% Upside As of April 2, ...

IQVIA (IQV) stock, ICON (ICLR) stock, and Fortrea (FTRE) stock were downgraded at Barclays, citing impact from potential pharma tariffs. Read more here.

Truist analyst Jailendra Singh lowered the firm’s price target on Iqvia (IQV) to $216 from $263 and keeps a Buy rating on the shares as part of ...

Barclays downgraded Iqvia (IQV) to Equal Weight from Overweight with a price target of $170, down from $235. The firm moved to the sidelines on ...